Piśmiennictwo
1. Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
2. Scott DL. The Diagnosis and prognosis of Early Arthritis: Rationale for New Prognostic Criteria. Arthritis Rheum 2002;46:286-90.
3. Sakellariou G, Scirè CA, Zambon A, et al. Performance of the 2010 classification criteria for rheumatoid arthritis: a systematic literature review and a meta-analysis. PLoS One 2013;8:e56528.
4. Radner H, Neogi T, Smolen JS, et al. Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2014;73:114-23.
5. Combe B, Machold K, Martin-Mola E, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
6. Corrao S, Argano C, Calvo L, et al. The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice. Intern Emerg Med 2015;10:271-5.
7. Mueller RB, Schiff M, Kaegi T, et al. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol 2015;34:51-9.
8. Schumacher HR Jr, Habre W, Meador R, et al. Predictive factors in early arthritis: long-term follow-up. Semin Arthritis Rheum 2004;33:264-72.
9. Finckh A. Early inflammatory arthritis versus rheumatoid arthritis. Curr Opin Rheumatol 2009;21:118-23.
10. Hazlewood G, Aletaha D, Carmena L, et al. Algorithm for identification of undifferentiated peripheral inflammatory arthritis: a multinational collaboration through the 3e initiative. J Rheumatol Suppl 2011;87:54-8.
11. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-26.
12. Hueber W, Utz PJ, Robinson WH. Autoantibodies in early arthritis: advances in diagnosis and prognostication. Clin Exp Rheumatol 2003;21 (suppl 31):59-64.
13. Schoels M, Bombardier C, Aletaha D. Diagnostic and prognostic value of antibodies and soluble biomarkers in undifferentiated peripheral inflammatory arthritis: a systematic review. J Rheumatol Suppl 2011;87:20-5.
14. Millot F, Clavel G, Etchepare F, et al. Musculoskeletal ultrasonography in healthy subjects and ultrasound criteria for early arthritis (the ESPOIR cohort). J Rheumatol 2011;38:613-20.
15. Minowa K, Ogasawara M, Murayama G, et al. Predictive grade of ultrasound synovitis for diagnosing rheumatoid arthritis in clinical practice and the possible difference between patients with and without seropositivity. Mod Rheumatol 2015;1-6.
16. Duer-Jensen A, Hørslev-Petersen K, Hetland ML, et al. Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis. Arthritis Rheum 2011;63:2192-2202.
17. Machado P, Castrejon I, Katchamart W, et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2011;70:15-24.
18. Pedersen JK, Lorenzen T, Ejbjerg B, et al. Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study. BMC Musculoskelet Disord 2014;15:268.
19. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
20. Mikuls TR, Payne JB, Yu F, et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66(5):1090-100.
21. Hawkins RA. Approach to the patient with monoarticular symptoms. W: Rheumatology secrets. West SG (red.). Hanley & Belfus, 2002: 88-94.
22. Hawkins RA. Approach to the patient with polyarticular symptoms. W: Rheumatology secrets. West SG (red.). Hanley & Belfus, 2002: 94-100.
23. Taylor P. Reumatoidalne zapalenie stawów w praktyce lekarskiej. Medycyna po Dyplomie (zeszyt edukacyjny) 2008;4(7).
24. Brzosko M. Choroby zapalne stawów u osób starszych – aspekty epidemiologiczne. Medycyna po Dyplomie, wydanie specjalne 18/06.
25. Tłustochowicz W, Brzosko M, et al. Stanowisko Zespołu Ekspertów Konsultanta Krajowego ds. Reumatologii w sprawie diagnostyki i terapii reumatoidalnego zapalenia stawów. Reumatologia 2008;46:111-4.
26. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
27. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxford) 2001;40:1211-20.
28. Machold KP, Nell VPK, Stamm TA, et al. Aspects of early arthritis. Traditional DMARD therapy: is it sufficient? Arthritis Res Ther 2006;8:211.
29. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
30. Van Dongen H, Van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007;55:1424-32.
31. Smolen JS, Aletaha D, Bijlsma JW, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
32. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-413.
33. Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence, with sustained benefit after inflikximab withdrawal. Arthritis Rheum 2005;52:27-35.
34. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.